Saptalis Pharmaceuticals and Coformer AI Partner to Develop Next-Generation Drug Formulations for Neurology and Oncology
Saptalis Pharmaceuticals and Coformer AI today announced a strategic research partnership to develop next-generation pharmaceutical formulations that address some of the industry's most persistent challenges, including poor solubility, low bioavailability, and dose-limiting toxicity. The collaboration will initially focus on neurology and oncology programs where improved formulation performance may translate into better therapeutic outcomes.
The partnership brings together Saptalis Pharmaceuticals' extensive expertise in formulation development with Coformer AI's proprietary Non-Covalent Derivatization (NCD) platform, combining the NCD chemistry pioneered by Coformer AI co-founder and Chief Science Officer John Warner with mechanistic AI models and closed-loop experimentation. Together, the companies aim to create differentiated formulations that enhance drug performance, support safer dosing strategies, and improve patient outcomes.
"This collaboration with Coformer AI represents the next phase of growth for Saptalis Pharmaceuticals as we expand our capabilities in advanced formulation innovation," said Polireddy Dondeti, CEO of Saptalis Pharmaceuticals. “Our formulation expertise, together with Coformer AI's advanced computational platform, enables us to develop innovative products that address unmet medical needs and improve patient outcomes, particularly in neurology and oncology."
